Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.84
PODD's Cash to Debt is ranked higher than
64% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. PODD: 0.84 )
PODD' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 0.84

Equity to Asset 0.27
PODD's Equity to Asset is ranked lower than
51% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. PODD: 0.27 )
PODD' s 10-Year Equity to Asset Range
Min: -2.37   Max: 0.73
Current: 0.27

-2.37
0.73
F-Score: 5
Z-Score: 5.46
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -3.45
PODD's Operating margin (%) is ranked higher than
61% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. PODD: -3.45 )
PODD' s 10-Year Operating margin (%) Range
Min: -43010   Max: -11.79
Current: -3.45

-43010
-11.79
Net-margin (%) -17.07
PODD's Net-margin (%) is ranked higher than
57% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. PODD: -17.07 )
PODD' s 10-Year Net-margin (%) Range
Min: -43272   Max: -18.2
Current: -17.07

-43272
-18.2
ROE (%) -46.13
PODD's ROE (%) is ranked higher than
53% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. PODD: -46.13 )
PODD' s 10-Year ROE (%) Range
Min: -278.45   Max: -53.3
Current: -46.13

-278.45
-53.3
ROA (%) -16.28
PODD's ROA (%) is ranked higher than
56% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. PODD: -16.28 )
PODD' s 10-Year ROA (%) Range
Min: -106.29   Max: -18.51
Current: -16.28

-106.29
-18.51
ROC (Joel Greenblatt) (%) -22.56
PODD's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. PODD: -22.56 )
PODD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1016.01   Max: -68.31
Current: -22.56

-1016.01
-68.31
Revenue Growth (%) 23.10
PODD's Revenue Growth (%) is ranked higher than
94% of the 261 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. PODD: 23.10 )
PODD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 101.6
Current: 23.1

0
101.6
EBITDA Growth (%) -30.10
PODD's EBITDA Growth (%) is ranked higher than
52% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. PODD: -30.10 )
PODD' s 10-Year EBITDA Growth (%) Range
Min: -72.6   Max: 25.9
Current: -30.1

-72.6
25.9
EPS Growth (%) -18.60
PODD's EPS Growth (%) is ranked higher than
59% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. PODD: -18.60 )
PODD' s 10-Year EPS Growth (%) Range
Min: -71   Max: 31.2
Current: -18.6

-71
31.2
» PODD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PODD Guru Trades in Q4 2013

Steven Cohen 622,777 sh (New)
Mariko Gordon 1,662,694 sh (+8.04%)
PRIMECAP Management 1,865,956 sh (unchged)
Jim Simons 186,500 sh (-3.12%)
Ron Baron 650,000 sh (-49.26%)
Pioneer Investments 31,798 sh (-84.45%)
» More
Q1 2014

PODD Guru Trades in Q1 2014

Jim Simons 364,900 sh (+95.66%)
PRIMECAP Management 1,966,756 sh (+5.4%)
Pioneer Investments 31,798 sh (unchged)
Ron Baron Sold Out
Mariko Gordon 1,631,242 sh (-1.89%)
Steven Cohen 18,121 sh (-97.09%)
» More
Q2 2014

PODD Guru Trades in Q2 2014

Ken Fisher 18,888 sh (New)
Pioneer Investments 217,166 sh (+582.95%)
Mariko Gordon 1,739,424 sh (+6.63%)
Steven Cohen 40,000 sh (unchged)
PRIMECAP Management 1,957,956 sh (-0.45%)
Jim Simons 167,200 sh (-54.18%)
» More
Q3 2014

PODD Guru Trades in Q3 2014

Louis Moore Bacon 130,000 sh (New)
Pioneer Investments 326,337 sh (+50.27%)
Jim Simons Sold Out
Steven Cohen Sold Out
PRIMECAP Management 1,956,456 sh (-0.08%)
Mariko Gordon 1,725,296 sh (-0.81%)
Ken Fisher 9,588 sh (-49.24%)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-09-30 Reduce -49.24%$32.94 - $41.11 $ 45.2624%9588
Mariko Gordon 2014-06-30 Add 6.63%0.17%$31.69 - $49.07 $ 45.2618%1739424
Ken Fisher 2014-06-30 New Buy$31.69 - $49.07 $ 45.2618%18888
Ron Baron 2014-03-31 Sold Out 0.1%$35.83 - $50.18 $ 45.263%0
Mariko Gordon 2013-12-31 Add 8.04%0.19%$34.7 - $39.86 $ 45.2623%1662694
Ron Baron 2013-12-31 Reduce -49.26%0.1%$34.7 - $39.86 $ 45.2623%650000
Mariko Gordon 2013-09-30 Reduce -5.99%0.15%$30.64 - $37.75 $ 45.2635%1538966
Mariko Gordon 2013-06-30 Add 173.36%1.59%$24.57 - $31.69 $ 45.2660%1637047
PRIMECAP Management 2013-03-31 Add 29.51%0.02%$21.02 - $25.86 $ 45.2696%1865956
David Swensen 2012-12-31 Sold Out 7.9%$19.13 - $22.15 $ 45.26113%0
David Swensen 2012-09-30 New Buy7.9%$18.72 - $22.14 $ 45.26118%79564
Ron Baron 2012-03-31 Add 29.4%0.03%$18.16 - $20.98 $ 45.26147%1063800
PRIMECAP Management 2012-03-31 Add 70.67%0.01%$18.16 - $20.98 $ 45.26147%972800
Ron Baron 2011-12-31 New Buy0.1%$14.29 - $18.98 $ 45.26166%822100
George Soros 2011-12-31 Sold Out 0.03%$14.29 - $18.98 $ 45.26166%0
PRIMECAP Management 2011-12-31 New Buy0.02%$14.29 - $18.98 $ 45.26166%570000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 31.65
PODD's P/B is ranked higher than
53% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. PODD: 31.65 )
PODD' s 10-Year P/B Range
Min: 3.13   Max: 1235
Current: 31.65

3.13
1235
P/S 8.79
PODD's P/S is ranked higher than
53% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. PODD: 8.79 )
PODD' s 10-Year P/S Range
Min: 1.34   Max: 25.53
Current: 8.79

1.34
25.53
Current Ratio 4.33
PODD's Current Ratio is ranked higher than
84% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. PODD: 4.33 )
PODD' s 10-Year Current Ratio Range
Min: 0.67   Max: 8.04
Current: 4.33

0.67
8.04
Quick Ratio 4.12
PODD's Quick Ratio is ranked higher than
86% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. PODD: 4.12 )
PODD' s 10-Year Quick Ratio Range
Min: 0.56   Max: 7.56
Current: 4.12

0.56
7.56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 90.52
PODD's Price/Tangible Book is ranked higher than
56% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.41 vs. PODD: 90.52 )
PODD' s 10-Year Price/Tangible Book Range
Min: 3.41   Max: 1123
Current: 90.52

3.41
1123
Price/Median PS Value 1.43
PODD's Price/Median PS Value is ranked higher than
62% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.20 vs. PODD: 1.43 )
PODD' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 3.16
Current: 1.43

0.22
3.16
Earnings Yield (Greenblatt) -0.40
PODD's Earnings Yield (Greenblatt) is ranked higher than
62% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. PODD: -0.40 )
PODD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -0.4

Forward Rate of Return (Yacktman) -32.00
PODD's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. PODD: -32.00 )
PODD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -381.1   Max: -32.6
Current: -32

-381.1
-32.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:GOV.Germany
Insulet Corp is a Delaware corporation formed in July 2000. The Company is engaged in the development, manufacturing and sale of OmniPod Insulin Management System. The OmniPod System is a disposable tubeless OmniPod worn on the body for approximately three days at a time. OmniPod Insulin Management System consists of disposable tubeless OmniPod worn on the body for approximatley three days at a time. The OmniPod System features two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. In October 2005 the Company began its commercial sale of OmniPod System in the United States. The Company sells OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through distribution partners. The OmniPod System is available in Europe through distribution partner, Ypsomed Distribution AG and in Canada through the distribution partner GlaxoSmithKline. The Company's sales and marketing effort is focused on generating demand and acceptance of the OmniPod System among diabetes practitioners, academic medical centers, clinics, insulin-dependent diabetes patients, third-party payors, government agencies, and third-party distributors. The marketing strategy is to build awareness for the benefits of the OmniPod System through education programs, social networking, patient demonstration programs, support materials, media advertisements and events at the national, regional and local levels. As of December 31, 2013, the Company had obtained 15 issued United States patents, and had 8 additional pending U.S. patent applications. It has registered the trademarks OMNIPOD, INSULET and the OMNIPOD design with the United States Patent and Trademark Office on the Principal Register. The OmniPod System competes with Medtronic MiniMed, Animas Corporation, Tandem Diabetes Care, Inc. and Roche Diagnostics, a division of F. Hoffmann-La Roche, Ltd.
» More Articles for PODD

Headlines

Articles On GuruFocus.com
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) May 07 2010 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Dec 23 2009 
Insulet Corp. (PODD) COO Luis Malave sells 5,116 Shares Nov 24 2009 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Nov 03 2009 
Insulet Corp. Reports Operating Results (10-Q) Oct 26 2009 
Insulet Corp. Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
INSULET CORP Financials Nov 14 2014
10-Q for Insulet Corp. Nov 07 2014
Insulet tops 3Q profit forecasts Nov 05 2014
Insulet tops 3Q profit forecasts Nov 05 2014
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Nov 05 2014
Insulet Corporation Appoints New Chief Financial Officer and Executive Vice President, Human... Nov 05 2014
Insulet Corporation Appoints New Chief Financial Officer and Executive Vice President, Human... Nov 05 2014
Insulet Reports Third Quarter 2014 Results Nov 05 2014
Q3 2014 Insulet Corp Earnings Release - After Market Close Nov 05 2014
Insulet Corporation to Present at Upcoming Investor Conferences Nov 03 2014
Insulet Corporation to Present at Upcoming Investor Conferences Nov 03 2014
Insulet Corporation to Report Third Quarter 2014 Financial Results on November 5, 2014 Oct 21 2014
Insulet Corporation to Report Third Quarter 2014 Financial Results on November 5, 2014 Oct 21 2014
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into... Oct 09 2014
INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Sep 16 2014
Insulet Corporation Appoints Patrick J. Sullivan as President and Chief Executive Officer Sep 16 2014
Insulet Corporation to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2014
INSULET CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Aug 15 2014
Insulet Appoints Timothy J. Scannell to Board of Directors Aug 15 2014
INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK